South Dakota Clinical Trials Report — July 2026

South Dakota residents who may qualify for a clinical trial should check closing dates now: 9 recruiting studies are expected to close within the next 90 days. Three of these studies accept healthy volunteers, creating a limited window for people without a diagnosed condition. The state has 320 recruiting trials across 13 cities and 142 research sites, but only 2 new studies opened in July, down from 4 in May.

Closing studies create the most immediate opportunity

The closing-soon list spans cancer, prevention, aging, skin disease, kidney stones, and cardiometabolic health. People who appear eligible should allow time for an application, prescreening, medical-record review, and any required testing. A projected closing date can change, so prospective participants should confirm that enrollment remains open directly with the study team.

• Atopic dermatitis — 1 closing-soon trial
• Brain health — 1
• Breast cancer — 1
• Breast cancer screening — 1
• Breast carcinoma in situ — 1
• Cardiometabolic health — 1
• Cognitive decline prevention in robust older adults — 1
• Healthy aging — 1
• Kidney and ureteral calculi — 1
• Malignancy — 1

Three of the nine closing studies accept healthy volunteers. Their topics include brain health, healthy aging, and prevention-oriented research, making them especially relevant to adults who do not have cancer or another active illness but want to contribute to research. South Dakota has 18 healthy-volunteer trials recruiting statewide overall, although none of the 2 new July trials accepts healthy volunteers.

A major Phase 3 lung-cancer study leads July’s new options

The most prominent new opening is Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study, NCT07680790. The trial plans to enroll 850 participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. It is evaluating izalontamab brengitecan, also called iza-bren, in combination with osimertinib against osimertinib alone or osimertinib combined with platinum-based chemotherapy.

This is a large, industry-sponsored drug study for people with a specific molecular form of lung cancer. Because eligibility depends on disease stage, prior treatment, and EGFR mutation status, patients and their oncologists will need to review pathology and treatment records carefully. The Phase 3 design and Bristol-Myers Squibb sponsorship make it a notable option for eligible patients seeking access to a comparative treatment study.

July’s other new trial is behavioral rather than drug-based. The new-trial activity touches mental health, substance use, trauma, sexual violence, suicide prevention, quality of life, and lung cancer. The supplied condition categories include:

• Depression and quality of life — 1 new trial
• Non-small cell lung cancer — 1
• Problem drinking — 1
• Post-traumatic stress disorder — 1
• Sexual violence — 1
• Suicidal ideation — 1

The month’s sponsor profile is split between industry and academic or other research. Bristol-Myers Squibb sponsored 1 new study, while the University of Michigan sponsored 1. The two openings include 1 drug trial and 1 behavioral trial, giving potential participants different types of research to consider.

New openings are concentrated in two communities

New July activity appeared in Pine Ridge and Sioux Falls, with 1 new trial in each city. Sioux Falls remains the state’s clearest medical-research hub based on the available July openings, while Pine Ridge shows that research opportunities are not limited to the largest metropolitan setting.

Statewide, the broader recruiting network reaches 13 cities and 142 research sites. That means the two July openings do not represent every location where South Dakota residents can seek a study. People should search across the full state rather than assume that a trial must be located in Sioux Falls. For behavioral or quality-of-life research, some screening or participation steps may also be possible remotely, but the study team must confirm the location and visit requirements.

Who should act now?

Patients with EGFR-mutant non-small cell lung cancer should review NCT07680790 promptly, particularly if they have not yet started treatment for locally advanced or metastatic disease. People with atopic dermatitis, breast-related conditions, kidney or ureteral stones, or an interest in brain health and healthy aging should focus on the nine studies approaching closure.

Healthy adults should also move quickly if they are considering one of the three closing studies that accepts healthy volunteers. Although 0 of July’s new trials accepts healthy volunteers, 18 other healthy-volunteer studies are recruiting somewhere in South Dakota. These opportunities may involve prevention, aging, cognition, or other research questions rather than treatment of a disease.

The eligibility profile for July is narrow. No new trial includes children, and no new trial is male-only. One is female-only, while 2 include older adults. Adults who fit those categories should read the eligibility details closely, especially where age, sex, mental-health history, cancer diagnosis, or prior treatment affects qualification.

New-trial openings have declined across the recent reporting period: July recorded 2, compared with 4 in June and May’s 4; the six-month sequence was 7 in February, 4 in March, 7 in April, 6 in May, 4 in June, and 2 in July. That slower pace makes the currently available studies more important to review. As August approaches, South Dakota residents can expect the recruiting landscape to shift again as closing studies leave the list and new behavioral, drug, cancer, and healthy-aging opportunities emerge.